Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Neurocrine Biosciences Inc (NASDAQ:NBIX)

48.65
Delayed Data
As of 3:59pm ET
 -0.245 / -0.50%
Today’s Change
37.35
Today|||52-Week Range
55.38
+25.70%
Year-to-Date
Biotech Movers: Inovio, Neurocrine, Alnylam
May 24 / TheStreet.com - Paid Partner Content
What Drug Approval Means for Neurocrine Biosciences
May 19 / GuruFocus News - Paid Partner Content

Today’s Trading

Previous close48.89
Today’s open49.24
Day’s range47.81 - 49.39
Volume2,236,312
Average volume (3 months)1,294,371
Market cap$4.7B
Dividend yield--
Data as of 3:59pm ET, 05/25/2017

Growth & Valuation

Earnings growth (last year)-55.24%
Earnings growth (this year)-50.68%
Earnings growth (next 5 years)+58.09%
Revenue growth (last year)-24.12%
P/E ratioNM
Price/Sales223.72
Price/Book14.77

Competitors

 Today’s
change
Today’s
% change
KITEKite Pharma Inc+3.25+4.54%
TECHBio-Techne Corp+0.14+0.13%
BLUEbluebird bio Inc+0.05+0.06%
BIVVBioverativ Inc+0.69+1.27%
Data as of 4:00pm ET, 05/25/2017

Financials

Next reporting dateAugust 2, 2017
EPS forecast (this quarter)-$0.64
Annual revenue (last year)$15.0M
Annual profit (last year)-$141.1M
Net profit margin-940.60%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Kevin Charles Gorman
President, Chief Operating &
Financial Officer
David-Alexandre C. Gros
Corporate headquarters
San Diego, California

Forecasts